What Is Melanotan II?
Melanotan II (MT-II) is a synthetic cyclic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH), developed at the University of Arizona in the 1980s as part of skin cancer prevention research. Researchers sought to stimulate the body's natural tanning response, melanogenesis, as a photoprotective mechanism against UV-induced DNA damage.
MT-II is distinguished from its predecessor, Melanotan I (afamelanotide), by its broader receptor activity. While Melanotan I acts primarily at the MC1R receptor to influence pigmentation, MT-II binds MC1R, MC3R, MC4R, and MC5R subtypes. This broader receptor profile extends its effects beyond tanning to include sexual function and appetite regulation, making it pharmacologically distinct from Melanotan I. MT-II has been colloquially called the "Barbie drug" in media coverage, a term originating in tabloid reporting rather than any scientific or regulatory designation.How It Works
Melanocortin Receptor Activation
Upon subcutaneous injection, MT-II enters systemic circulation and binds to melanocortin receptors. The MC1R receptor on melanocytes mediates the primary tanning response. Binding triggers cyclic adenosine monophosphate (cAMP) signaling, which stimulates tyrosinase activity and increases eumelanin production, the brown-black pigment responsible for darker skin tone. This mechanism produces a more sustained and deeply pigmented tan compared to UV exposure alone.
Sexual Function Enhancement
MC4R receptors in the hypothalamus and central nervous system mediate the pro-sexual effects of MT-II. Unlike phosphodiesterase-5 inhibitors such as sildenafil, which act peripherally on vascular smooth muscle, MT-II works centrally to initiate arousal through dopaminergic pathways. This central mechanism of action is what led to the development of bremelanotide (PT-141), a related melanocortin peptide that received FDA approval for hypoactive sexual desire disorder in women.
Appetite and Energy Regulation
MC3R and MC4R receptors in the hypothalamus play a role in regulating feeding behavior and energy balance. Research demonstrates that MT-II activation at these receptors reduces food intake and may influence fat metabolism, contributing to the appetite suppression commonly reported by users.
Pharmacokinetics
Peak plasma concentrations occur within 1–2 hours post-injection. MT-II has a half-life of approximately 1–2 hours. Despite this relatively short plasma half-life, biological effects on melanogenesis persist longer due to sustained melanin production in melanocytes once the signaling cascade has been initiated.